Sichuan Kelun Pharmaceutical Co., Ltd.'s (SZSE:002422) Prospects Need A Boost To Lift Shares
Jun 11
Chinese (SSE) Pharma Industry Analysis
UpdatedJun 15, 2024
DataAggregated Company Financials
Companies220
- 7D-1.1%
- 3M-4.5%
- 1Y-12.5%
- YTD-9.8%
Over the last 7 days, the Pharma industry has dropped 1.1%, driven by declines in China Resources Sanjiu Medical & Pharmaceutical and Sichuan Biokin PharmaceuticalLtd of 7.4% and 4.8%, respectively. In contrast, Haisco Pharmaceutical Group has gained 9.3%. Overall the industry is down 13% in 12 months. As for the next few years, earnings are expected to grow by 18% per annum.
Industry Valuation and Performance
Has the Chinese Pharma Industry valuation changed over the past few years?
| Date | Market Cap | Revenue | Earnings | PE | Absolute PE | PS |
|---|---|---|---|---|---|---|
| Sat, 15 Jun 2024 | CN¥2.5t | CN¥805.5b | CN¥74.6b | 27.7x | 33.6x | 3.1x |
| Mon, 13 May 2024 | CN¥2.8t | CN¥821.6b | CN¥77.5b | 31.9x | 36.2x | 3.4x |
| Wed, 10 Apr 2024 | CN¥2.6t | CN¥828.5b | CN¥78.2b | 28.7x | 33.4x | 3.1x |
| Fri, 08 Mar 2024 | CN¥2.5t | CN¥831.9b | CN¥80.7b | 26.2x | 31.2x | 3x |
| Sun, 04 Feb 2024 | CN¥2.2t | CN¥831.4b | CN¥79.9b | 23.4x | 28x | 2.7x |
| Tue, 02 Jan 2024 | CN¥2.8t | CN¥827.8b | CN¥79.7b | 31x | 35.3x | 3.4x |
| Thu, 30 Nov 2023 | CN¥2.9t | CN¥819.4b | CN¥78.7b | 31.6x | 36.8x | 3.5x |
| Sat, 28 Oct 2023 | CN¥2.8t | CN¥825.1b | CN¥78.8b | 31.2x | 35x | 3.3x |
| Mon, 25 Sep 2023 | CN¥2.7t | CN¥824.8b | CN¥78.6b | 31.2x | 34.8x | 3.3x |
| Wed, 23 Aug 2023 | CN¥2.6t | CN¥815.9b | CN¥77.6b | 30.4x | 33.5x | 3.2x |
| Fri, 21 Jul 2023 | CN¥2.7t | CN¥811.0b | CN¥76.9b | 31.3x | 35.6x | 3.4x |
| Sun, 18 Jun 2023 | CN¥2.9t | CN¥809.7b | CN¥76.5b | 31.8x | 37.4x | 3.5x |
| Tue, 16 May 2023 | CN¥3.0t | CN¥809.1b | CN¥76.5b | 32.8x | 38.6x | 3.6x |
| Thu, 13 Apr 2023 | CN¥3.0t | CN¥797.0b | CN¥91.2b | 34.1x | 32.7x | 3.7x |
| Sat, 11 Mar 2023 | CN¥2.9t | CN¥778.0b | CN¥83.4b | 37.3x | 34.5x | 3.7x |
| Mon, 06 Feb 2023 | CN¥2.9t | CN¥774.7b | CN¥83.1b | 36x | 35.3x | 3.8x |
| Wed, 04 Jan 2023 | CN¥2.8t | CN¥771.4b | CN¥82.1b | 34.5x | 33.6x | 3.6x |
| Fri, 02 Dec 2022 | CN¥2.8t | CN¥767.8b | CN¥81.9b | 36.2x | 34.3x | 3.7x |
| Sun, 30 Oct 2022 | CN¥2.6t | CN¥766.6b | CN¥81.9b | 33.6x | 31.5x | 3.4x |
| Tue, 27 Sep 2022 | CN¥2.3t | CN¥760.3b | CN¥79.5b | 29.1x | 28.8x | 3x |
| Thu, 25 Aug 2022 | CN¥2.6t | CN¥754.1b | CN¥81.1b | 30.5x | 31.5x | 3.4x |
| Sat, 23 Jul 2022 | CN¥2.7t | CN¥744.7b | CN¥81.0b | 31.4x | 33.9x | 3.7x |
| Mon, 20 Jun 2022 | CN¥2.7t | CN¥739.6b | CN¥82.0b | 32.1x | 33.1x | 3.7x |
| Wed, 18 May 2022 | CN¥2.6t | CN¥740.3b | CN¥81.7b | 32.5x | 31.6x | 3.5x |
| Fri, 15 Apr 2022 | CN¥2.7t | CN¥724.5b | CN¥76.1b | 33.2x | 35.2x | 3.7x |
| Sun, 13 Mar 2022 | CN¥2.9t | CN¥727.1b | CN¥77.5b | 34x | 36.9x | 3.9x |
| Tue, 08 Feb 2022 | CN¥2.7t | CN¥721.5b | CN¥73.6b | 32.3x | 37.3x | 3.8x |
| Thu, 06 Jan 2022 | CN¥3.1t | CN¥720.5b | CN¥73.8b | 37.6x | 42.3x | 4.3x |
| Sat, 04 Dec 2021 | CN¥3.0t | CN¥718.2b | CN¥73.3b | 32.1x | 41.1x | 4.2x |
| Mon, 01 Nov 2021 | CN¥2.8t | CN¥714.7b | CN¥70.6b | 29x | 39.5x | 3.9x |
| Wed, 29 Sep 2021 | CN¥2.9t | CN¥702.7b | CN¥71.2b | 31.4x | 40.2x | 4.1x |
| Fri, 27 Aug 2021 | CN¥2.8t | CN¥702.6b | CN¥71.1b | 29.8x | 38.8x | 3.9x |
| Sat, 03 Jul 2021 | CN¥3.2t | CN¥697.2b | CN¥70.2b | 32.4x | 46.1x | 4.6x |
Price to Earnings Ratio
46.1x
Current Industry PE
- Investors are relatively neutral on the Chinese Pharmaceuticals industry at the moment, indicating that they anticipate long term growth rates to remain steady.
- The industry is trading close to its 3-year average PE ratio of 35.7x.
- The 3-year average PS ratio of 3.6x is higher than the industry's current PS ratio of 3.1x.
Past Earnings Growth
- The earnings for companies in the Pharmaceuticals industry have grown 2.0% per year over the last three years.
- Revenues for these companies have grown 4.9% per year.
- This means that more sales are being generated by these companies overall, and subsequently their profits are increasing too.
Industry Trends
Which industries have driven the changes within the Chinese Healthcare industry?
| CN Market | 0.061% | |
| Healthcare | -0.73% | |
| Pharma | -1.12% | |
| Pharma | -1.12% | |
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.
Top Stock Gainers and Losers
Which companies have driven the market over the last 7 days?
| Company | Last Price | 7D | 1Y | Valuation | |
|---|---|---|---|---|---|
| 2653 Haisco Pharmaceutical Group | CN¥33.20 | 9.3% +CN¥3.1b | 40.2% | PE102.2x | |
| 2294 Shenzhen Salubris Pharmaceuticals | CN¥28.54 | 4.7% +CN¥1.4b | -12.8% | PE54.7x | |
| 603520 Zhejiang Starry PharmaceuticalLtd | CN¥10.19 | 0.4% +CN¥990.9m | -40.0% | PE95.2x | |
| 766 Tonghua Golden-Horse Pharmaceutical Industry CoLtd | CN¥17.28 | 6.1% +CN¥966.5m | 260.8% | PE380.1x | |
| 2422 Sichuan Kelun Pharmaceutical | CN¥32.36 | 1.5% +CN¥747.7m | 7.4% | PE19.3x |
